Table 3. Comparison of D0 exacerbation characteristics of patients given SCS versus patients not given SCS for which p < 0.1 (see S1 Appendix for all other characteristics evaluated).
| Characteristic | Exacerbation | ||
|---|---|---|---|
| n = 81 Events | |||
| SCS | No SCS | P-value | |
| n = 64 | n = 17 | ||
| LAMA, n (%) | 13 (20) | 10 (59) | 0.00 |
| PPI, n (%) | 4 (6) | 5 (29) | 0.01 |
| Eosinophils %* | 1.9 (0.4–4.8) | 0.8 (0.2–1.1) | 0.01 |
| Increased wheeze at exacerbation, n (%) | 58 (91) | 12 (71) | 0.03 |
| Blood pCO2 (kPa)* | 5.7 (5.1–6.1) | 4.8 (4.5–5.7) | 0.05 |
| Total number of ITU admissions in previous 12 months* | 0 (0–0) | 0 (0–1) | 0.05 |
| SCS in week prior to exacerbation admission, n (%) | 33 (52) | 13 (76) | 0.07 |
| Leucocytes (x10⁹cells/L)* | 10.2 (8.8–12.8) | 11.9 (10.6–14.0) | 0.08 |
| Oxygen saturation (%)˜ | 95 (86–100) | 96 (91–100) | 0.09 |
Definition of abbreviations: LAMA = Long-acting muscarinic antagonist; PPI = proton pump inhibitor; ITU = intensive therapy unit.
Measures of central tendency and spread: variables marked with the * symbol are presented as median (IQR); variables marked with the ˜ symbol are presented as mean (range). Comparisons between SCS and no SCS group are made using chi-squared, wilcox test or t-test as appropriate. P-values are reported to 2dp unless the p-value is less than 0.001, in which case it is reported as <0.001.